A specific monoclonal antibody of azoxystrobin and an immunological detection kit thereof

By introducing a carboxyl active group onto the molecule of azoxystrobin to prepare a hapten and synthesizing azoxystrobin monoclonal antibody, the problem of the lack of specific antibodies against azoxystrobin was solved, realizing efficient and simple detection of azoxystrobin residues and filling a technological gap.

CN123042200APending Publication Date: 2026-11-06XINUOTONGKE (TIANJIN) BIOTECHNOLOGY CO LTD +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611570114.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-12
Publication Date
2026-11-06

AI Technical Summary

Technical Problem

Current technologies lack monoclonal antibodies and immunological detection methods for azoxystrobin. The molecular structure of azoxystrobin lacks active groups suitable for protein coupling, which makes it impossible to directly stimulate animals to produce specific antibodies. Furthermore, existing detection methods are expensive and complex to operate, making it difficult to meet the needs of rapid screening of large-scale samples.

Method used

A hapten was prepared by introducing a carboxyl active group onto the pyraclostrobin molecule, and a pyraclostrobin monoclonal antibody was synthesized. Hybridoma cell lines were screened using a PEG-mediated cell fusion method, and a monoclonal antibody that specifically recognizes pyraclostrobin was prepared. An enzyme-linked immunosorbent assay kit was also developed.

Benefits of technology

A monoclonal antibody against azoxystrobin was prepared, exhibiting good sensitivity and specificity, with an IC50 of 40-60 ng/mL and a cross-reactivity rate of less than 0.1%. The ELISA detection kit is easy to operate and suitable for batch screening of azoxystrobin residues in agricultural products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123042200A_ABST
    Figure CN123042200A_ABST
Patent Text Reader

Abstract

This invention discloses a monoclonal antibody that specifically recognizes azoxystrobin and its application. The heavy and light chain variable regions of the monoclonal antibody have specific complementarity-determining region sequences, and the half-maximal inhibitory concentration (IC50) for azoxystrobin is [not specified]. 50 The concentration is 40-60 ng / mL, and the cross-reactivity with tebuconazole and triadimefon is less than 0.1%, exhibiting good sensitivity and excellent specificity. This invention fully discloses the CDR sequence and full-length variable region sequence of this antibody (SEQ ID NO. 1-32), filling the technological gap in the field of monoclonal antibodies against azoxystrobin and providing a clear sequence resource for antibody engineering. The enzyme-linked immunosorbent assay (ELISA) kit developed based on this antibody is suitable for rapid and sensitive detection of azoxystrobin residues in agricultural products and has promising application prospects.
Need to check novelty before this filing date? Find Prior Art